Devices and methods for transdermal drug delivery

• US 10,238,847 B2
• Filed: 01/22/2015
• Issued: 03/26/2019
• Est. Priority Date: 01/22/2014
• Status: Active Grant

• Current Assignee: Brain Tunnelgenix Technologies Corp.
• Original Assignee: Geelux Holdings, Ltd.
• Inventors: Abreu, Marcio Marc
• Primary Examiner(s): Marcetich, Adam
• Application Number:
  US14/603,353
• Publication Number:
  US 20150202417A1
• Time in Patent Office: 1,524 Days
• CPC Class Codes: A61B 5/01 Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue clinical contact thermometers G01K13/20
• CPC Class Codes: A61F 2007/0003 Face
• CPC Class Codes: A61F 2007/0052 for treatment of skin or hair
• CPC Class Codes: A61F 2007/0075 using a Peltier element, e.g. near the spot to be heated or cooled
• CPC Class Codes: A61F 2007/026 with a fluid absorbing layer
• CPC Class Codes: A61F 2007/0261 medicated
• CPC Class Codes: A61M 2205/3368 Temperature
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 35/10 Wearable devices, e.g. garments, glasses or masks

Abstract

Provided are devices for therapeutic interaction with an Abreu brain thermal tunnel (ABTT) terminus. Such devices are configured to provide one or more drugs to an ABTT terminus, and may provide heat to or remove heat from the ABTT terminus while providing the one or more drugs.

Claims

1. A device configured to deliver a drug transdermally to the skin of a face feeding an Abreu brain thermal tunnel (ABTT), the device comprising:

a curvilinear device support;

a first drug container having a first, drug delivery side, a second side on an opposite side of the first drug container from the first, drug delivery side, and at least one connecting side extending between the first, drug delivery side and the second side; and

a first thermoelectric device positioned directly in contact alongside the at least one connecting side of the first drug container;

the first drug container and the first thermoelectric device being commonly supported in the curvilinear device support for transdermal delivery of a drug from the first drug container, the curvilinear device support being shaped and configured to deliver the drug transdermally to the skin by permeating the skin and flowing into at least one of a frontal vein, an angular vein, a supraorbital vein, and a superior vein,

the curvilinear device support having a first end configured to be positioned in a region between a patient'"'"'s eye and a patient'"'"'s eyebrow, and a second end configured to be positioned in a region between the patients eye and a patient'"'"'s nose,

the first end including a first transverse width positioned a first longitudinal length from the first end along a centerline of the curvilinear device support, the first transverse width is 15 mm+/−

8 mm, and the first longitudinal length is 7.5 mm+/−

5 mm,

the second end including a second transverse width positioned a second longitudinal length from the second end along the centerline of the curvilinear device support, the second transverse width is greater than or equal to the first transverse width and the second longitudinal length is approximately equal to the first longitudinal length.

2. The device of claim 1, further including a second drug container and a second thermoelectric device positioned adjacent the second drug container.

3. The device of claim 2, wherein when the device is positioned on the skin of the face, the temperature of the first thermoelectric device and the temperature of the second thermoelectric device is adjusted to control delivery of a first drug from the first drug container and a second drug from a second drug container through the skin of the face.

4. The device of claim 1, wherein the drug delivered transdermally to the skin permeates the skin of an ABTT terminus and flows into the ABTT.

5. A device configured to deliver a drug transdermally to the skin of a face feeding an Abreu brain thermal tunnel (ABTT), the device comprising:

a curvilinear device support for placement between the eye and the eyebrow, and measuring in its largest dimension 22 mm;

a first drug container positioned on the curvilinear device support, the first drug container having a first, drug delivery side, a second side on an opposite side of the first drug container from the first, drug delivery side, and at least one connecting side extending between the first, drug delivery side and the second side;

a first thermoelectric device positioned directly in contact alongside the at least one connecting side of the first drug container;

the curvilinear device support commonly supporting the first drug container and the first thermoelectric device for transdermal delivery of a drug from the first drug container, the curvilinear device support being shaped and configured to deliver the drug transdermally to the skin by permeating the skin and flowing into at least one of a frontal vein, an angular vein, a supraorbital vein, and a superior vein,

the curvilinear device support having a first end configured to be positioned in a region between a patient'"'"'s eye and a patient'"'"'s eyebrow, and a second end configured to be positioned in a region between the patients eye and a patient'"'"'s nose,

the first end including a first transverse width positioned a first longitudinal length from the first end along a centerline of the curvilinear device support, the first transverse width is 15 mm+/−

8 mm, and the first longitudinal length is 7.5 mm+/−

5 mm,

the second end including a second transverse width positioned a second longitudinal distance from the second end along the centerline of the curvilinear device support, the second transverse width is approximately equal to the first transverse width and the second longitudinal distance is approximately equal to the first longitudinal distance.

6. The device of claim 5, including a second drug container, the first drug container positioned closer to the first end than the second end and the second drug container positioned closer to the second end than the first end.

7. The device of claim 6, including a third drug container positioned between the first drug container and the second drug container.

8. The device of claim 6, wherein the first drug container includes a first drug, the second drug container includes a second drug, and the first drug is different from the second drug.